COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

• Authors: BUSCA Alessandro; SALMANTON-GARCÍA Jon; CORRADINI Paolo; MARCHESI Francesco; CABIRTA Alba; BLASI Roberta Di; DULERY Remy; LAMURE Sylvain; FARINA Francesca; WEINBERGEROVÁ Barbora; BATINIĆ Josip; NORDLANDER Anna; LÓPEZ-GARCÍA Alberto; DRGOŇA Ľuboš; ESPIGADO-TOCINO Ildefonso; FALCES-ROMERO Iker; GARCÍA-SANZ Ramón; GARCÍA-VIDAL Carolina; GUIDETTI Anna; KHANNA Nina; KULASEKARARAJ Austin; MAERTENS Johan; HOENIGL Martin; KLIMKO Nikolai; KOEHLER Philipp; PAGLIUCA Antonio; PASSAMONTI Francesco; CORNELY Oliver A; PAGANO Livio
• Year of publication: 2022
• Type: Article in Periodical
• Magazine / Source: Blood advances
• MU Faculty or unit: Faculty of Medicine
• Web: https://ashpublications.org/bloodadvances/article/6/7/2427/477883/COVID-19-and-CAR-T-cells-a-report-on-current
• Doi: http://dx.doi.org/10.1182/bloodadvances.2021005616
• Keywords: Clinical Trials and Observations; Immunobiology and Immunotherapy; Stimulus Report
• Description: The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.